Welcome to Gallus Biopharmaceuticals, LLC.

What's in a name? In Mark Bamforth's (Gallus' President & CEO) native Scotland, "gallus" means self-confident, daring, impressive or, in the local vernacular "pure dead brilliant." What better name to call a new company than Gallus Biopharmaceuticals (aka Gallus) when the vision of the company is to become the partner of choice for biotech and pharmaceutical companies who want a dependable, dedicated manufacturer for their products.

Self-confidence: Gallus was created with the goal of taking a high quality, high performing team with a storied history of developing and producing biopharmaceuticals for big pharma parents, and infusing this team with an entrepreneurial vision to build a world-class Contract Manufacturing Organization.

The Gallus team at the company's site in St Louis has routinely delivered commercial product for use by patients around the world for over a decade and has a history of product development stretching back over 25 years with several parent companies. The site has been inspected and approved by every major regulatory body including the FDA, EMA, HealthCanada, ANVISA and MHRA.

Daring to create a new CMO model: This site will be expanded using the latest disposable or single-use technology developed by Gallus' partner and the technical leader in this field, Xcellerex, thus providing clients with a rapid response to their product capacity needs. Gallus will be a new model of CMO with unprecedented access to capacity through a virtual ownership model where clients can "own" a suite, have a permanent presence in the suite and have data feeds to their own base.

The demand for capacity is increasing, fueled by the $65B annual investment in R&D for biological treatments for diseases and the growing trend to outsource development and manufacturing. The Gallus team independently confirmed the market analysis with potential clients in advance of the facility acquisition.

Impressive business plan: To make the business a reality required significant financial backing. Gallus has partnered with a private equity partner, Ridgemont Equity Partners, with deep experienced gained from investing over $3B in 140 investments throughout an 18 year history. This investment, together with support from Founders and Management, strong State and County support and a line of credit from an enterprising local bank.

Now the business is poised to build a strong, sustainable presence in St Louis by continuing to manufacture commercial products for the recent site owner and by bringing in new clients' development and commercial products. This growth is enabled by an initial investment of over $20M to establish new development labs, a clinical suite and commercial capacity.

Gallus is open for business and focused on creating sustainable growth through the delivery of the vision to become the partner of choice for the industry.